Skip to main content
OpenTrials
Completed

NCT Number: NCT01019889

Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection

The purpose of this study is to determine whether Socheongryong-tang (SCRT) and Yeongyopaedok-san (YPS) are effective in the treatment of upper respiratory tract infection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

Upper respiratory tract infections (URTIs) are the most prevalent disease of human beings, it incur a significant health burden on populations in terms of human suffering and economic losses. Usually, antibiotic therapy is not helpful since most infections are virally induced. Over 200 serologically different viral types are responsible for human URTIs, so that preventions of URTIs including vaccination are impassable. SCRT and YPS are widely used to treat the respiratory disease. The objective of this study is to determine the efficacy of SCRT and YPS in symptomatic relief of patients with URTIs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18~60 years old
  • Clinical diagnosis of common cold
  • Occurring no longer than 48 hours before enrollment
  • Presented with runny nose, sore throat, plugged nose, scratchy throat, cough, hoarseness, headache, muscle ache (runny nose, sore throat and at least 1 of others or 1 of runny nose, sore throat and at least 3 of others)

Exclusion criteria

  • Allergic rhinitis, asthma, COPD, sinusitis (2 and more recurrence per year), septal deviation, anatomical otitis media, exudative pharyngitis
  • Received antihistamines, NSAIDs, corticosteroids, antibiotics, decongestants
  • Hepatic cancer, liver cirrhosis, renal failure, congestive heart failure
  • Pregnant or lactation

Treatment and study plan

SCRT

Drug

4 capsules,three times daily, for 7days or within symptom disappearance

Other names: Xiao-qing-long-tang

YPS

Drug

4 capsules, three times daily, for 7days or within symptom disappearance

Other names: Lian-qiao-bai-du-san

Placebo

Drug

4 capsules, three times daily, for 7days or within symptom disappearance

Primary outcomes

  1. Changes of score daily measured by WURSS-K before, during and after treatment

    Time frame: daily (7 days)

Secondary outcomes

  1. Time of symptom disappearance

    Time frame: daily

  2. Changes of score daily measured by WURSS-K before, during and after treatment in pattern identification

    Time frame: daily (7days)

Sponsors and collaborators

Lead sponsor

Korea Health Industry Development Institute

Other Gov

Registry information

Acronym: ESYUI

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Nov 25, 2009
Registry last updated
Apr 6, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.